Model combining genomic and clinical factors to predict clinical benefit from PD1/PD-L1 inhibitors for advanced UC

被引：0
|
作者：
Nassar, Amin
Mouw, Kent William
Liu, Chia-Jen
Lundgren, Kevin
Van Allen, Eliezer Mendel
Harshman, Lauren Christine
Pomerantz, Mark
Preston, Mark A.
Wei, Xiao X.
McGregor, Bradley Alexander
Choudhury, Atish Dipankar
Bellmunt, Joaquim
Choueiri, Toni K.
Kwiatkowski, David J.
Sonpavde, Guru
机构：
[1] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA
[2] Dana Farber Canc Inst, Brookline, MA USA
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
[4] Stanford Univ, Sch Med, Stanford, CA 94305 USA
[5] David Grant Med Ctr, Benicia, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.4539
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4539
引用
收藏
页数：1
相关论文
共 50 条
  • [31] PD-1/PD-L1 inhibitors
    Sunshine, Joel
    Taube, Janis M.
    CURRENT OPINION IN PHARMACOLOGY, 2015, 23 : 32 - 38
  • [32] Outstanding clinical efficacy of PD-1/PD-L1 inhibitors for pulmonary pleomorphic carcinoma
    Lee, Jiyun
    La Choi, Yoon
    Jung, Hyun Ae
    Lee, Se-Hoon
    Ahn, Jin Seok
    Ahn, Myung-Ju
    Park, Keunchil
    Sun, Jong-Mu
    EUROPEAN JOURNAL OF CANCER, 2020, 132 : 150 - 158
  • [33] Inhibition of PD1:PD-L1 interaction by an E-coli-derived optimized PD1 variant
    Shwartz, Michal Brand
    Assor, Mayan
    Dotan, Nesly
    Ratzon, Einav
    Cohen, Elad
    Ruimi, Nili
    Bloch, Itai
    Gal, Maayan
    Yadid, Itamar
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2018, 506 (03) : 731 - 738
  • [34] Ongoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer in China
    Liu, Si-Yang
    Wu, Yi-Long
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2017, 10
  • [35] Ongoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer in China
    Si-Yang Liu
    Yi-Long Wu
    Journal of Hematology & Oncology, 10
  • [36] PD-1/PD-L1 pathway inhibitors in advanced prostate cancer
    Velho, Pedro Isaacsson
    Antonarakis, Emmanuel S.
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2018, 11 (05) : 475 - 486
  • [37] PD-L1 expression and PD-1/PD-L1 inhibitors in breast cancer
    Monneur, Audrey
    Goncalves, Anthony
    Bertucci, Francois
    BULLETIN DU CANCER, 2018, 105 (03) : 261 - 272
  • [38] Clinical benefit of neoadjuvant anti-PD-1/PD-L1 utilization among different tumors
    Li, Zhiyang
    Wu, Xin
    Zhao, Yanjie
    Xiao, Yinan
    Zhao, Yunuo
    Zhang, Ting
    Li, Hui
    Sha, Fushen
    Wang, Yating
    Deng, Lei
    Ma, Xuelei
    MEDCOMM, 2021, 2 (01): : 60 - 68
  • [39] Clinical benefits of PD-1/PD-L1 inhibitors in advanced hepatocellular carcinoma: a systematic review and meta-analysis
    Quan Rao
    Min Li
    Wei Xu
    Kai Pang
    XiaoBo Guo
    Dong Wang
    Jun Liu
    Wei Guo
    ZhongTao Zhang
    Hepatology International, 2020, 14 : 765 - 775
  • [40] Biological Characteristics and Clinical Significance of Soluble PD-1/PD-L1 and Exosomal PD-L1 in Cancer
    Niu, Mengke
    Liu, Yiming
    Yi, Ming
    Jiao, Dechao
    Wu, Kongming
    FRONTIERS IN IMMUNOLOGY, 2022, 13
12345